„DON“ compounds

Boc-DON-Gln-Ile-Val-OMe, Boc-DON

10 mg 385 € available

Art. No. B003
Synonym tert.-Butyloxycarbonyl-(6-Diazo-5-oxonorleucinyl)-LGlutaminyl-L-Isoleucinyl-L-Valinmethylester
Molecular Formula C28H47N7O9
Molecular Weight 625.7
Purity by HPLC >95 % (HPLC)
Appearance yellow solid
Solubility 1.5 mM in 2% (v/v) DMSO / aqueous buffers.
Pre-dissolve e.g. 4.69 mg (7.5 μmol) in 100 μl DMSO - dilute by adding 4.9 ml buffer to obtain a 1.5 mM solution.
DMSO stock solutions can be stored at -20°C for at least 6 months. To avoid too many freeze-thaw cycles, we strongly recommend storage of aliquots.
Application Irreversible inhibitor of tissue transglutaminase; IC50 ~ 0.3 μM
Storage store at -20°C, desiccate
Reference(s) Verhaar et al., Neurochem. Int. 2011, 58:785-93
Schaertl et al., J. Biomol. Screen. 2010, 15:478-87
McConoughey et al., EMBO Mol. Med. 2010, 2:1-22
Zeugolis et al., J. Biomed. Mater. Res. 2
010, 15:1310-20
Kristen et al., Circ. Res. 2008, 102:529-37
Mádi et al., Anal. Biochem. 2005, 343:256-62
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy